Merck Financials

MRK Stock  USD 83.01  1.41  1.67%   
Merck Company may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Merck's Net Debt is quite stable compared to the past year. Non Current Assets Total is expected to rise to about 90 B this year, although the value of Cash will most likely fall to about 5.6 B. Key indicators impacting Merck's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Net Profit Margin0.00660.007
Notably Down
Slightly volatile
Return On Assets0.00370.0039
Notably Down
Pretty Stable
Return On Equity0.01060.0112
Notably Down
Very volatile
Debt Equity Ratio0.910.87
Sufficiently Up
Slightly volatile
Operating Income5.6 B3.4 B
Way Up
Slightly volatile
Current Ratio1.621.44
Moderately Up
Slightly volatile
The financial analysis of Merck is a critical element in measuring its lifeblood. Investors should not minimize Merck's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Cash And Equivalents

9.29 Billion

  

Merck Company Earnings Geography

Merck Stock Summary

Merck competes with AbbVie, Pfizer, Eli Lilly, Bristol Myers, and Amgen. Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 67000 people.
Foreign Associates
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNew York Stock Exchange
ISINUS58933Y1055
CUSIP58933Y105 589331107
LocationNew Jersey; U.S.A
Business Address126 East Lincoln
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.merck.com
Phone908 740 4000
CurrencyUSD - US Dollar

Merck Key Financial Ratios

Merck Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets91.6B105.7B109.2B106.7B122.7B128.8B
Other Current Liab14.7B15.6B16.0B17.5B20.1B21.1B
Net Debt23.7B25.0B18.0B29.4B33.8B35.5B
Retained Earnings47.4B53.7B61.1B53.9B62.0B32.6B
Cash8.1B8.1B12.7B6.8B7.9B5.6B
Net Receivables7.2B9.2B9.5B10.3B11.9B12.5B
Inventory6.3B6.0B5.9B6.4B7.3B3.7B
Other Current Assets6.9B7.0B7.2B8.4B9.6B10.1B
Total Liab66.2B67.4B63.1B69.0B79.4B83.4B
Total Current Assets27.8B30.3B35.7B32.2B37.0B19.2B
Short Term Debt6.7B2.4B1.9B1.7B1.9B2.3B
Intangible Assets14.6B22.9B20.3B18.0B20.7B14.3B
Accounts Payable4.3B4.6B4.3B3.9B4.5B2.8B
Other Liab12.7B12.1B11.7B9.1B10.5B10.2B
Other Assets5.3B7.8B9.4B7.4B8.5B5.5B
Long Term Debt25.4B30.7B28.7B33.7B38.7B40.7B
Good Will20.2B21.3B21.2B21.2B24.4B12.3B
Treasury Stock(56.8B)(57.1B)(56.5B)(57.5B)(51.7B)(54.3B)
Net Tangible Assets(7.7B)(9.5B)3.5B4.5B4.1B4.5B

Merck Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense831M806M962M1.1B1.3B1.4B
Total Revenue41.5B48.7B59.3B60.1B69.1B72.6B
Gross Profit27.9B35.1B41.9B44.0B50.6B53.1B
Operating Income6.1B13.7B19.4B3.0B3.4B5.6B
Ebit6.7B14.7B17.4B3.0B3.5B5.6B
Ebitda10.2B17.9B21.3B6.9B7.9B8.4B
Cost Of Revenue13.6B13.6B17.4B16.1B18.5B11.7B
Income Before Tax8.8B13.9B16.4B1.9B2.2B2.1B
Net Income7.1B13.0B14.5B365M419.8M398.8M
Income Tax Expense1.7B1.5B1.9B1.5B1.7B2.0B
Research Development13.4B12.2B13.5B30.5B35.1B36.9B
Minority Interest15M691M(7M)(13M)(11.7M)(11.1M)
Non Recurring638M578M661M337M303.3M288.1M
Tax Provision1.7B1.5B1.9B2.8B3.3B2.2B
Interest Income59M1.9B1.3B390M448.5M732.6M
Net Interest Income(772M)(770M)(805M)(681M)(612.9M)(643.5M)

Merck Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory(855M)(674M)(161M)(816M)(734.4M)(697.7M)
Change In Cash(1.8B)14M4.6B(5.9B)(5.3B)(5.0B)
Free Cash Flow5.6B9.7B14.7B9.1B10.5B6.7B
Depreciation3.6B3.2B3.9B3.9B4.5B3.1B
Other Non Cash Items4.3B1.7B4.5B12.2B14.1B14.8B
Dividends Paid6.2B6.6B7.0B7.4B8.6B9.0B
Capital Expenditures4.7B4.4B4.4B3.9B4.4B4.7B
Net Income7.1B12.4B14.5B365M419.8M398.8M
End Period Cash Flow8.2B8.2B12.8B6.9B7.9B6.2B
Change To Netincome2.1B1.5B2.8B2.0B2.3B2.4B
Investments1.7B1.0B(483M)(15.9B)(14.3B)(13.6B)
Change Receivables294M(1.0B)(2.0B)(644M)(579.6M)(550.6M)
Net Borrowings1.2B5.0B1.6B(2.3B)(2.0B)(1.9B)

Merck Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Merck's current stock value. Our valuation model uses many indicators to compare Merck value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Merck competition to find correlations between indicators driving Merck's intrinsic value. More Info.
Merck Company is regarded fourth in return on equity category among its peers. It is regarded third in return on asset category among its peers reporting about  0.25  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Merck Company is roughly  3.96 . At this time, Merck's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Merck by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Merck Company Systematic Risk

Merck's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Merck volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Merck Company correlated with the market. If Beta is less than 0 Merck generally moves in the opposite direction as compared to the market. If Merck Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Merck Company is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Merck is generally in the same direction as the market. If Beta > 1 Merck moves generally in the same direction as, but more than the movement of the benchmark.

Merck Thematic Clasifications

Merck Company is part of several thematic ideas from Giant Impact to Compulsion. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Merck Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Merck's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Merck growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(8.72)

At this time, Merck's Price Earnings To Growth Ratio is quite stable compared to the past year.

Merck February 16, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Merck help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Merck Company. We use our internally-developed statistical techniques to arrive at the intrinsic value of Merck Company based on widely used predictive technical indicators. In general, we focus on analyzing Merck Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Merck's daily price indicators and compare them against related drivers.
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.33)
Dividend Share
3.08
Earnings Share
6.74
Revenue Per Share
25.253
Quarterly Revenue Growth
0.068
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.